

**PRODUCTION AND CHARACTERIZATION OF NDV IGY FROM TWO DIFFERENT CHICKEN BREEDS****Salwa Mohamed Hezema<sup>1</sup>, Samy Kasem<sup>2</sup>, Emad Eldin Elgendy<sup>1</sup>, Madiha Salah Ibrahim<sup>1\*</sup>**<sup>1</sup>Department of Microbiology, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.<sup>2</sup>Department of Virology, Faculty of Veterinary Medicine, Kafr ElShiek University, Kafr ElShiek, Egypt.**\*Corresponding Author: Madiha Salah Ibrahim**

Department of Microbiology, Faculty of Veterinary Medicine Damanhour University, Damanhour, Egypt.

Article Received on 20/05/2020

Article Revised on 09/06/2020

Article Accepted on 30/06/2020

**ABSTRACT**

This study aimed to prepare hyper-immune chicken IgY against Newcastle disease virus (NDV) and studying its immunogenicity against field isolates of NDV. Ten white Hy-line layers, and ten local house breeds were used. The birds received an initial immunization followed by two booster doses at time intervals of 2 weeks. Throughout the experiment (8-11) weeks, serum samples were collected weekly with daily egg collection. The purified IgY specificity and titers in sera and egg yolk were determined using HI and neutralization tests against NDV vaccinal strain and field isolates. Significant titers of IgY were detected against NDV with comparable neutralization efficacy for the two breeds. Thus, both hen breeds can be efficiently used for production of protective IgY against NDV field isolates.

**KEYWORDS:** NDV, IgY, HI, Neutralization test.**1. INTRODUCTION**

IgY is an immunoglobulin in egg yolk that is transferred from the maternal circulation to confer passive immunity to embryos and neonates (Rose et al., 1974). The amount of IgY transported is known to be proportional to the maternal serum IgY concentration (Loeken and Roth, 1983). IgY technology was approved by animal welfare organizations and workshops such as the Veterinary Office of the Swiss Government (Office Vétérinaire Fédéral) and the European center for the validation of alternative methods (ECVAM) workshop to be used to support animal welfare (Schade, 1997). IgY has been widely used nowadays for immunodiagnostics and/or for treatment and prevention of infections in humans and animals (Miller, 2010.).

Recently, passive immunization using chicken egg yolk (IgY) has become an attractive approach with considerable attention as it possesses a variety of advantages over mammalian IgG as convenience, high yield, effectiveness and low cost (Carlander et al., 2000.). Therefore, the vast amount of available antibodies open the door for new fields of IgY application, such as immunotherapy and immune prophylaxis for several bacterial and viral infections in both human and veterinary fields (Losch et al., 1986; Schade and Hlinak, 1996; Muhammed, et al., 2001; Carlander, 2002).

Newcastle disease (ND) is one of the most important viral diseases (Orsi et al., 2010) affecting wild and

domestic avian species (Seal et al., 2000 and Alexander, 2000) causing respiratory and nervous disorders in several species of poultry including chicken and turkeys (Lancaster, 1976). NDV is highly contagious, with high morbidity and mortality in susceptible birds (up to 100%) (OIE, 2012). Notification is required by OIE of any outbreak of ND (Cao et al., 2013). Vaccination for protecting chicken against ND is routinely practiced throughout the world, but the vaccination is ineffective with the high titer of maternal antibodies (Rahman, et al., 2002; Marangon, and Capua, 2006), thus, alternative protection early in chicks' life is of great importance. Therefore, our study aimed to prepare hyperimmunized eggs from two different chicken breeds and evaluate the different levels of IgY production among both breeds as well as assessing the neutralizing and detection capabilities of the produced IgY against NDV.

**2. MATERIAL AND METHODS****2.1. Chicken**

Ten local house breed (28 weeks) and ten white Hy-line (48 weeks) laying hens were used. Hens were purchased from Al-madina farm for layers, Cairo-Alexandria desert road and housed in animal facility joined with the Department of Microbiology, Faculty of Veterinary Medicine, Damanhour University. They were used for immunization and kept in separate cages. The hens received commercial rations (110g per hen) and water ad libitum.

## 2.2. Vaccine and adjuvant

Live attenuated laSota vaccine with HA titer  $2^9$  was used for vaccination (KBNP, INC., Korea). Complete and incomplete Freund's adjuvants were obtained from Sigma-Aldrich US.

## 2.3. Experimental design and immunization schedule

Hens were subcutaneously immunized with an initial dose of 300 $\mu$ l of Lasota virus vaccine emulsified with equal volume of Freund's complete adjuvant, then subsequently followed by three subcutaneous booster doses using incomplete Freund's adjuvant (Nahla *et al.*, 2018).

## 2.4. Serum Samples

Blood samples were collected regularly every week. Serum samples were collected and stored at -20°C for detection of specific antibodies. The eggs were daily collected throughout the entire period of the experiment (11 weeks) and stored at 4°C.

## 2.5. Extraction of egg yolk and Purification of IgY

The egg shell was sterilized and broken then the yolk was separated. The egg yolk was washed with sterile double distilled water without puncturing of yolk membrane. Yolk contents were collected in a sterile container. Egg yolk was diluted 10 times in sterile PBS (Yokoyama *et al.*, 1998). The IgY was purified from the egg yolk by direct freezing and thawing according to Jensenius and Koch, (1997). The supernatant containing IgY was filtered and stored at -20°C till used.

## 2.6. Hemagglutination inhibition test (HI)

The HI test using the serum and the purified IgY was carried out according to OIE, (2015).

## 2.7. Neutralization test

Neutralization test was carried out according to the method adopted by Ohishi *et al.*, (1994). Briefly, ten-fold serial dilutions of purified IgY were incubated in equal volumes with 100 EID<sub>50</sub> virus (LaSota virus vaccine) and incubated for 60 minutes at 37°C then each dilution was inoculated into the allantoic cavity of five embryonated eggs. End- points of the IgY titers were determined according to Reed and Muench, (1938). They were expressed as reciprocals of log<sub>10</sub> dilutions.

## 2.8. Field samples testing

Field samples from chickens (lungs) with NDV infection clinical and postmortem picture were collected from infected farms in Damanhour city, Beheria Government. Lung samples were ground, purified then inoculated in 9-11-day old chicken embryo eggs WHO, (2002). Allantoic fluid was collected and processed to HI test using the purified IgY. Two lung samples were ground, purified and were directly used in HI test using the purified IgY.

## 3. RESULTS


### 3.1. Evaluation of serum and yolk antibody titer from immunized chicken breeds against NDV

The antibody titer against NDV in serum and egg yolk were measured in white-Hy line breed (WHL) and local house breed (LB) by HI test before immunization and weekly thereafter. Serum antibody titer of the pre-immunized LB was  $2^6$ , which increased after the initial immunization to  $2^9$  at the 2<sup>nd</sup> and 3<sup>rd</sup> weeks. Thereafter, the titer decreased to  $2^6$  and  $2^4$  at 4<sup>th</sup> and 5<sup>th</sup> week, respectively. After the 2<sup>nd</sup> booster dose at the 6<sup>th</sup> week the titer increased to  $2^{12}$ ,  $2^{12}$  and  $2^{11}$  at 7<sup>th</sup>, 8<sup>th</sup> and 9<sup>th</sup> week, respectively (Table 1 and Fig. 1). In contrast, the yolk antibody titer of the pre-immunized LB was  $2^6$ , which increased after immunization to  $2^7$  at 4<sup>th</sup> week after the initial dose by 2 weeks and then decreased gradually to  $2^6$ ,  $2^6$ ,  $2^5$ ,  $2^4$  and  $2^5$  at 5<sup>th</sup>, 6<sup>th</sup>, 7<sup>th</sup>, 8<sup>th</sup> and 9<sup>th</sup> week, respectively as shown in (Table 1 and Fig. 1).

On the other hand, the serum antibody titer of the pre-immunized WHL was  $2^7$ , which increased to  $2^9$  at 2<sup>nd</sup> week then  $2^8$  at the 3<sup>rd</sup> week after the initial immunization. Then decreased to  $2^6$  at 4<sup>th</sup> week and re-increased after 1<sup>st</sup> booster dose and 2<sup>nd</sup> booster dose to  $2^{10}$ ,  $2^{11}$  and  $2^{12}$  at 5<sup>th</sup>, 6<sup>th</sup> and 7<sup>th</sup> week, respectively. Thereafter the titer decreased to  $2^{11}$  at 8<sup>th</sup> and 9<sup>th</sup> week and to  $2^{10}$  at 10<sup>th</sup> and 11<sup>th</sup> week (Table 1 and Fig. 2). On the other hand, the pre-immunized yolk antibody titer of WHL was  $2^2$ , which increased to  $2^5$  at 2<sup>nd</sup> and 3<sup>rd</sup> week after the initial immunization. Thereafter the titer increased to  $2^8$  at 4<sup>th</sup> and 5<sup>th</sup> week after the 1<sup>st</sup> booster dose. The titer increased again from  $2^6$  at 6<sup>th</sup> week to  $2^8$  at 7<sup>th</sup> week after 2<sup>nd</sup> booster then decreased to  $2^4$ ,  $2^6$ ,  $2^5$  and  $2^5$  at 8<sup>th</sup>, 9<sup>th</sup>, 10<sup>th</sup> and 11<sup>th</sup> week, respectively (Table 1 and Fig. 2).

**Table 1: Post-immunization serum and yolk antibody titers by HI test.**

Week	White HY-line breed		Local house breed	
	Samples	HI Antibody titers	Sample	HI Antibody titer
Pre-immunization titer week 1	Yolk Serum	$2^2$ $2^7$	Yolk serum	$2^6$ $2^6$
Week 2 (Initial dose)	Yolk Serum	$2^5$ $2^9$	Yolk serum	$2^6$ $2^9$
Week 3	Yolk Serum	$2^5$ $2^8$	Yolk serum	$2^6$ $2^9$
Week 4 (1st booster dose)	Yolk Serum	$2^8$ $2^6$	Yolk serum	$2^7$ $2^6$
Week 5	Yolk Serum	$2^8$ $2^{10}$	Yolk serum	$2^6$ $2^4$
Week 6 (2nd booster dose)	Yolk Serum	$2^6$ $2^{11}$	Yolk serum	$2^6$ $2^5$
Week 7	Yolk Serum	$2^8$ $2^{12}$	Yolk serum	$2^5$ $2^{12}$
Week 8	Yolk Serum	$2^4$ $2^{11}$	Yolk serum	$2^4$ $2^{12}$
Week 9	Yolk serum	$2^6$ $2^{11}$	Yolk serum	$2^5$ $2^{11}$
Week 10	Yolk serum	$2^5$ $2^{10}$		
Week 11	Yolk Serum	$2^5$ $2^{10}$		

**Figure 1: Serum and yolk antibody titers of LB following immunization.**




Figure 2: Serum and yolk antibody titer of WHL following immunization.

### 3.2. Antibody transfer from serum to yolk against NDV in LB and WHL

The antibody transfer percent ranged from 0.39% to 400% in LB, with the highest percentage on the 5<sup>th</sup> week after the first booster dose and lowest percent at 8<sup>th</sup> week (Table 2 and Fig. 3). While, the antibody transfer percent

ranged from 0.78% to 400% in WHL, with the highest percentage on 4<sup>th</sup> week (two weeks after initial immunization) and lowest percent at 8<sup>th</sup> week as shown in Table (2) and Fig. (3). The results showed that the highest transfer in LB was during 4<sup>th</sup>, 5<sup>th</sup> and 6<sup>th</sup> week while, for WHL was during the 4<sup>th</sup> week only.

Table (2): Percentage of antibody transfer against NDV in LB and WHL breeds

Week	LB	WHL
Pre-immunization titer (w1)	100%	3.125%
Week 2 (Initial dose)	12.5%	6.25%
Week 3	12.5%	12.5%
Week 4 (1 <sup>st</sup> booster dose)	200%	400%
Week 5	400%	25%
Week 6 (2 <sup>nd</sup> booster dose)	200%	3.125%
Week 7	0.78125%	6.25%
Week 8	0.390625%	0.78125%
Week 9	1.5625%	3.125%
Week 10		3.125%
Week 11		3.125%

Percentage of transfer of antibodies from the serum to the egg yolk =  $\text{yolk antibody titer} / \text{serum antibody titer} \times 100$  (Hamal *et al.*, (2006), Kowalczyk *et al.*, (2019).




Figure (3): Percentages of antibody transfer from serum to yolk in LB and WHL.

### 3.3. Specificity and protective efficiency of egg yolk antibody from LB and WHL breeds against NDV

The highest egg yolk antibody titer from LB ( $2^7$  at 4<sup>th</sup> week) and from WHL ( $2^8$  at 7<sup>th</sup> week) were tenfold serially diluted. Then different dilutions of the yolk antibody were mixed with NDV ( $10^{5.6}$  EID<sub>50</sub>) then inoculated in ECE to calculate the neutralization index.

The results showed that the protection with LB-derived IgY was 100% for  $10^{-1}$  and  $10^{-2}$ , 60% for  $10^{-3}$  and  $10^{-4}$  and 40% for  $10^{-5}$  and  $10^{-6}$ . While, the protection with WHL-derived IgY was 100% for  $10^{-1}$ ,  $10^{-2}$  and  $10^{-3}$ , 80% for  $10^{-4}$  and  $10^{-5}$  and 70% for  $10^{-6}$  (Table 3). The neutralization index value for LB-derived IgY was  $10^{3.9}$ /ml in contrast to  $10^{4.2}$ /ml for WHL-derived IgY.

Table (3): The percent of LB and WHL egg yolk antibody protection against NDV in ECE

IgY titer	Percent of egg protection in WHL	Percent of egg protection in LB
$10^{-1}$	100%	100%
$10^{-2}$	100%	100%
$10^{-3}$	100%	60%
$10^{-4}$	80%	60%
$10^{-5}$	80%	40%
$10^{-6}$	70%	40%


### 3.4. Neutralization efficiency of LB and WHL egg yolk antibodies against NDV field isolates

Seven NDV field samples were used to determine the efficiency of egg yolk antibodies produced from both LB and WHL breeds. Lungs were collected and homogenized. Five sample were propagated in embryonated chicken eggs and two isolates were used

without previous egg inoculation. The HA titers of the seven samples ranged from  $10^3$  to  $10^{11}$ . These viruses were neutralized by  $2^7$  and  $2^8$  egg yolk antibodies for LB and WHL, respectively. The HI titer of the egg yolk ranged from  $10^4$  to  $10^{10}$  for LB and WHL, respectively as shown in Table 4 and Fig. 4. The LB IgY showed one log higher HI titers as compared to the WHL IgY.

Table 4: Egg yolk antibody titer of LB and WHL against NDV field isolates.

Sample number	Type of sample	Virus titer	Egg yolk antibody titer by HI	
			WHL ( $2^8$ )	LB ( $2^7$ )
1	Allantoic fluid	$10^9$	$10^6$	$10^7$
2	Allantoic fluid	$10^6$	$10^7$	$10^8$
3	Allantoic fluid	$10^7$	$10^8$	$10^9$
4	Allantoic fluid	$10^4$	$10^4$	$10^5$
5	Allantoic fluid	$10^3$	$10^9$	$10^{10}$
6	Lung	$10^{11}$	$10^{10}$	$10^{11}$
7	Lung	$10^{11}$	$10^9$	$10^{10}$



**Figure (4):** Egg yolk antibody titer of LB and WHL against NDV field isolates. 1-5; allantoic fluid samples, 6 and 7; lung samples.

#### 4. DISCUSSION

laying hens are highly cost-effective as producers of antibodies compared to mammals (Larsson *et al.*, 1993). Average volume of egg yolk (15 mL) contains 50–100 mg of IgY, of which 2%–10% can be of specific antibodies, this is a much higher amount of immunoglobulin that could be obtained by bleeding the animal (Sudjarwo, *et al.*, 2012; Ferreira *et al.*, 2012). The IgY has been applied successfully in diagnostics, prophylactic, therapeutic purposes, immunochemical reagents and in food formulation or supplements due to its stability under food processing conditions (Raj *et al.*, 2004 and Schade *et al.*, 2006). In our study, IgY was produced from different chicken breeds. The neutralization efficiency by NT in ECE and HI test with laSota vaccine strain and NDV field isolates was tested.

Our results showed that egg yolk antibody titer reached the peak after the initial immunization to 2<sup>7</sup> and 2<sup>8</sup> at the 4<sup>th</sup> week in LB and WHL, respectively. Furthermore, the serum antibody titer reached a peak after the 2<sup>nd</sup> booster dose to 2<sup>12</sup> at the 7<sup>th</sup> week in both LB and WHL chickens. These results indicate that IgY titer in egg yolk in LB is slightly lower by one log than WHL. It was reported that there are significant differences between breeding groups for antibody titer responses to Newcastle disease (Peleg *et al.*, 1980; Gyles *et al.*, 1986; Atta *et al.*, 1990; Siam *et al.*, 1994; El-Gendy *et al.*, 1995; Li *et al.*, 2001; Hassan *et al.*, 2004; Chang *et al.*, 2011), furthermore, the serum antibody titer decreased when the yolk titer increased, which means that there is a reverse relationship between the serum titer and yolk titer. The serum IgY titer was higher during all weeks of collection except at the 5<sup>th</sup> week for WHL, and the 4<sup>th</sup> to 6<sup>th</sup> week for the LB chicken where the titer was higher in

the yolk. This indicates a longer maintenance of high yolk antibody titers in LB than WHL. This was also detected with the antibody transfer where it was much more efficient in the LB (5<sup>th</sup> and 6<sup>th</sup> week) as compared to the WHL (4<sup>th</sup> week) indicating a possible better fitting of LB chicks following hatching, possessing higher levels of protection. However, this may be due to differences in the age, genetic makeup or physiological status between both breeds. This was in contrast to Agrawal *et al.* (2016) who showed that there are no hen line differences in IgY transfer from serum to yolk.

The neutralization index for WHL (10<sup>4.2</sup>) was slightly higher than that for LB (10<sup>3.9</sup>). In contrast, the results obtained from the neutralization of IgY and field NDV isolates showed that even the IgY titer of LB (2<sup>7</sup>) was one log lower than WHL (2<sup>8</sup>), the LB IgY showed slightly higher neutralization efficiency than WHL IgY. Marked breed, strain and line differences have been reported for various immunological traits (Cheng and Lamont, 1988; Baelmans *et al.*, 2005). Some investigations were done on the intensity of antibody production and wattle reaction to natural antigens showed that both humoral and cellular immune reactivity to sheep red blood cells were breed dependent in contrast to those against *Brucella abortus* crude antigen (Benda *et al.*, 1990).

In conclusion, our results indicated that both LB and WHL breeds can produce IgY with high titer and good neutralization efficiency against both laSota virus vaccine and field ND viruses without significant differences. Both IgYs can be possibly used for protection and/or prophylaxis against NDV. Further studies are required to evaluate the protective potentials



of egg antibodies against other types of ND viruses with higher virulence that threaten the poultry population in Egypt. Moreover, monitoring egg yolk antibodies can be a good tool for monitoring the maternal vaccination efficiency in a farm without hen interference.

## 5. REFERENCES

1. Agrawal, R., S. D. Hirpurkar, C. Sannat, and A. K. Gupta. (2016): Comparative study on immunoglobulin Y transfer from breeding hens to egg yolk and progeny chicks in different breeds of poultry. *Vet. World*, 9: 425–431.
2. Alexander, D. J. (2000): Newcastle disease, other avian paramyxoviruses. *Rev Sci Tech*, Aug; 19(2): 443-62. DOI: 10.20506/rst.19.2.1231.
3. Atta, A.M., (1990): A genetical study on the White Baladi fowl. Ph. D. Thesis, Fac. Of Agriculture, Cairo Univ. Egypt.
4. Baelmans R, Parmentier HK, Nieuwland MGB, Dorny P, Demey F (2005): Serological screening for MHC (B)- polymorphism in indigenous chickens. *Trop. Anim. Health Prod*, 37(2): 93-102.
5. Benda, V., Hampl, A., Trtkova, K. (1990): Evaluation of wattle reaction and antibody response in different chicken breeds. *Acta. Vet. Brno*, 59: 151-156. Doi: 10.2754/avb199059030151.
6. Cao, Y., Gu, M., Zhang, X., Liu, W., Liu, X. (2013): Complete Genome Sequences of Two Newcastle Disease Virus Strains of Genotype VIII. *J. Genome Announcements*, 1(1): 01.
7. Carlander, D., Kolberg, H., Wejaker, P. and Larsson, A. (2000): Perioral immunotherapy with yolk antibodies for the prevention and treatment of enteric infection. *Immunol. Res*, 21: 1-6.
8. Carlander, D. (2002): Avian IgY antibody. In vitro and in vivo. *Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala. Dissertation from the Faculty of Medicine*, 1119: 153.
9. Chang, C.S., Boichard, M.T., Chazara, O., Lee, Y.P., Chen, C.F., Chang, P.C., Chen, J.W. and Bedhom, B. (2011): Different immune responses to three different vaccines following H6N1 low pathogenic avian influenza virus challenge in Taiwanese local chicken breeds. *BMC Proceedings*, 2011; Jun 3;5 Suppl. 4: S33. DOI: 10.1186/1753-6561-5-S4-S33.
10. Cheng S, Lamont SJ. (1988): Breeding and genetic analysis of immunocompetence in White Leghorn chicken line. *Poult Sci*, 67: 989–995.
11. El-Gendy, E.A., A.A. Atallah, F.R. Mohamed, A.M. Atta and N.E. Goher, (1995): Strain variation in young chickens in response to chronic heat stress conditions. *Egypt. J. Anim. Prod*, 32: 237-251.
12. Ferreira Júnior, Á., Santiago, FM., Silva, MV., Ferreira, FB., Macêdo Júnior, AG. and Mota, CM., et al. (2012): Production, characterization and applications for toxoplasma gondii-specific polyclonal chicken egg yolk immunoglobulins. *PLoS One*, 7(7): e40391. Doi: 10.1371/journal.pone.0040391.
13. Gyles, N.R., H.F. Moghadam, L.T. Patterson, L.K. Skeeles, G.E. Whitfill and L.W. Johanson, (1986): Genetic aspects of antibody response in chickens to different classes of antigens. *Poult. Sci*, 65: 223-232.
14. Hamal, KR., Burgess, S.C., Pevzner, LY., Erf, G.F. (2006): Maternal Antibody Transfer from Dams to Their Egg Yolks, Egg Whites, and Chicks in Meat Lines of Chickens. *Poult. Sci*, 85(8): 1364-1372.
15. Hassan, M.K., Afify, M.A. and Aly, M.M. (2004.): Genetic Resistance of Egyptian Chickens to Infectious Bursal Disease and Newcastle Disease. *Tropical Animal Health and Production*, 36(1): 1-9.
16. J. H. and H. van Eck (1987): Immunity to Newcastle disease in fowl of different breeds, primarily vaccinated with commercial inactivated oil-emulsion vaccines: A laboratory experiment, *Veterinary Quarterly*, 9:4, 296-303, DOI: 10.1080/01652176.1987.9694117.
17. Jensenius, J.C. and Koch, C. (1997): Antibodies packaged in eggs, in immunochemistry A practical approach. (Johnstone, A.P. and Turner. M.W., eds). IRL press, Oxford, UK, 1: 89-107.
18. Kowalczyk J., Smialek M., Tykalowski B., Dziewulska D., Stenzel T., and Koncicki A. (2019): Field evaluation of maternal antibody transfer from breeder turkey hens to egg yolks, egg whites, and poult. *Poultry Science*, 98: 3150–3157.
19. Lancaster, JE. (1976): A history of Newcastle disease with comments on its economic effects. *World Poult. Sci. J*, 32: 167-175.
20. Larsson, A., Balow, R., Lindahl, T.I. and Forsberg, P.O. (1993): Chicken antibody Taking advantage of evolution review. *Poult. Sci*, 72(10): 1807.
21. Li, Z., K.E. Nestor, Y.M. Saif, J.W. Anderson and R.A. Patterson, (2001): Effect of Selection for Increased Body Weight in Turkeys on Lymphoid Organ Weights, Phagocytosis and Antibody Responses to Fowl Cholera and Newcastle Disease-Inactivated Vaccines. *Poultry Science*, 80: 689-694.
22. Loeken, M. Rs., and T.F. Roth. (1983): Analysis of maternal IgG subpopulation, which are transported into chicken oocyte. *Immunology*, 49: 21-28.
23. Losch, U., Schraner, I., Wanke, R. and Jürgens, L. (1986): The chicken egg, an antibody source. *J. Vet. Med*, 33(1- 10): 609-619.
24. Marangon S. and Capua I. (2006): Control of avian influenza in Italy: from stamping out to emergency and prophylactic vaccination. *Dev. Biol*, 124: 109-115.
25. Miller, P.J., E.L. Decanini and C.L. Afonso (2010): Newcastle disease: Evolution of genotypes and the related diagnostic challenges. *Infect. Genet. Evol*, 10: 26-35.
26. Muhammed K., Rabbi F., Hussain I. and Hussain T. (2001): passive immunization Against Infections Bursal Disease in chicks. *Int J Agri & Biol*, 3(4): 413-415.
27. Nahla, M. F., Abd-elfattah, N. A., Ibrahim M. S., (2018): Characterization of chicken IgY produced against H5 and H9 avian influenza viruses AJVS,

- 59(1): 79-91. Oct. 2018 DOI: 10.5455/ajvs.297644
28. Orsi, MA., Doretto, Jr., L., Camillo, SCA., Reischak, D., Ribeiro, SAM., Ramazzoti, A., Mendonça, AO., Spilki, FR., Buzinaro, MG., Ferreira, HL. and Arns, CW. (2010). Prevalence of Newcastle disease virus in Broiler chickens (*Gallus gallus*) in Brazil. *Brazilian J. Microbiol*, 41: 349-35.
  29. Ohishi, K., Senda, M., Yamamoto, H., Nagai, H., Norimatsu, M. and Sasaki, H. (1994): Detection of avian encephalomyelitis viral antigen with a monoclonal antibody. *Avian Pathol*, 23: 49-59.
  30. OIE terrestrial manual, (2015): Chapter 2.3.4. avian influenza (infection with avian influenza viruses).
  31. OIE, (2012): Manual of Diagnostic Tests and Vaccines for Terrestrial Animals: Mammals, Birds and Bees, Biological Standards Commission. World Organization for Animal Health, Paris, 1–19.
  32. Peleg, B., N. Ron-kuper and K. Hornstein, (1980); Genetic and phenotypic correlations between immune response to *Escherichia coli* and to Newcastle disease virus vaccines. *Poult. Sci*, 59: 49-53. 2 June 2010.
  33. Rahman MM., Bar SM, Giasuddin M., Islam MR., Alam J. and Sil GC. (2002); Evaluation of Maternal and Humoral immunity against Newcastle Disease virus in chicken. *Int J poult sci*, 1(5): 161-163.
  34. Raj, GD., Latha, B. and Chandrasekhar, MS. (2004): Production, characterization and application of monoclonal antibodies against chicken IgY. *Vet. Arch*, 2004; 74(3).
  35. Reed, L.J., Muench and H.A. (1938): A simple method of estimating fifty per cent endpoints. *Am J. Hyg*, 27: 493–497.
  36. ROSE, M.E., Orlans, E., Buttress and Nglobulin. (1974): Immunoglobulin classes in the hen's eggs their segregation in yolk and white.. *Eur. J. Immunol*, 4(7): 521-523.
  37. Schade, R. and Hlinak, A., (1996): Egg Yolk Antibodies. State of the Art and Future Prospects. *ALTEX*, 13: 5-9.
  38. Schade, R. and Terzolo, H.R. (2006.): IgY-technology: application and trends. 12th European WPSA). Poultry Conference. Verona, Italy. Beekbergen: World's Poultry Science Association.
  39. Schade, R., Staak, C., Hendriksen, C., Erhard, MH., Hugel, H., Koch, G., Larsson, A., Pollmann, W., van Regenmortel, M., Rijke, E., Spielmann, H., Steinbusch, H. and Straughan, D. (1997): The production of avian (egg yolk) antibodies: IgY. The report and recommendations of ECVAM workshop 21. *ATLA*, 24: 925–934.
  40. Siam and S.M., (1994): Environmental and physiological studies on domestic and local new strains of poultry. Ph.D. Thesis, Fac. of Agric. Cairo, Univ. Egypt.
  41. Seal, B. S.; King, D. J. and Sellers, H. S. (2000): The avian response to Newcastle disease virus. *Develop.Comp. Immunol*, 24: 257-268.
  42. Sudjarwo, SA., Sudjarwo, EK., Koerniasari, (2012): Purification and characterization protein of anti-dengue specific immunoglobulin Y for diagnostic kit of dengue. *J Appl Pharm Sci*, 2(12): 7–12.
  43. WHO/CDS/CSR/NCS (2002): WHO Manual on Animal Influenza Diagnosis and Surveillance WHO/CDS/CSR/NCS/2002.5 - WHO animal influenza manual.
  44. Yokoyama, H., Peralta, Re., H., Diaz, R. and Sendo, S. (1998): passive protective effect of chicken egg yolk immunoglobulins against experiment enterotoxigenic *Escherichia coli* infection in neonatal piglets. *Infect & immune*, 60(3): 1007.